Randomised Controlled Trial Of Cognitive Behaviour Therapy To Prevent Psychosis Among People With At-risk Mental States.
Funder
National Health and Medical Research Council
Funding Amount
$619,604.00
Summary
Recent advances in the accurate identification of individuals at high risk of developing a psychotic disorder, such as schizophrenia, have inspired the development of interventions designed to delay, ameliorate or even prevent the onset of such disorders. To date, the results of only three randomised controlled trials of such interventions have been published. Although these results have shown that interventions are able to delay the onset of psychosis, and may even prevent psychosis in some cas ....Recent advances in the accurate identification of individuals at high risk of developing a psychotic disorder, such as schizophrenia, have inspired the development of interventions designed to delay, ameliorate or even prevent the onset of such disorders. To date, the results of only three randomised controlled trials of such interventions have been published. Although these results have shown that interventions are able to delay the onset of psychosis, and may even prevent psychosis in some cases, it is unclear which treatment should be preferred for this population because the three trials have assessed, respectively, a combination of anti-psychotic medication and cognitive behaviour therapy (CBT), CBT alone, and anti-psychotic medication alone. Since the trial of CBT alone produced results that were at least as favourable as the two other trials, and since ethical and clinical objections have been raised concerning the use of anti-psychotic medications with young people who may never develop a psychotic disorder, CBT may be the preferred treatment. Far from posing unnecessary risks, CBT has the potential to provide important therapeutic benefits even to those not destined to develop a psychosis. The current study is significant in that it proposes a controlled trial of a form of CBT which has been specially adapted for preventing transition to psychosis among young high-risk individuals, to test whether the previous favourable results for CBT can be independently replicated. It will be compared with a control treatment. Since cannabis abuse is common among young people who are at risk, and is a known risk factor for psychosis, CBT will include elements of treatment for cannabis abuse. The trial will be run in both Newcastle and Orange, NSW, enabling us to compare the effectiveness of CBT in urban and rural settings. This study has the potential to have large impacts on the quality of life of young people at risk of psychosis.Read moreRead less
Antipsychotic Medication In First-episode Psychosis: An RCT To Assess The Risk-benefit Ratio
Funder
National Health and Medical Research Council
Funding Amount
$1,141,117.00
Summary
There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do no harm” and benefits must outweigh the risks of treatment. While antipsychotic medication is very effective and evidence-based form of treatment for positive symptoms in most first episode psychosis (FEP) patients it has risks. This study has the potential to determine whether antipsychotic medication should be the initial treatment option for FEP.
PSYSCAN— Translating Neuroimaging Findings From Research Into Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$376,285.00
Summary
Our ability to predict the onset and outcome of schizophrenia and other psychotic disorders remains limited. This restricts the implementation of effective preventative and early interventions. This project will rectify this by developing a tool of significant clinical utility. The project has 2 aims: 1. To develop and validate a neuroimaging-based tool for use in early psychosis to assist with early diagnosis, outcome, and disease progression. 2. To apply the tool in clinical practice.
Long-term Outcome Of Individuals Who Had A First-episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$1,344,905.00
Summary
The long-term illness course and outcomes of patients treated for first episode psychosis are poorly understood especially in terms of important domains such as social and vocational functioning, physical health, and quality of life. This treated cohort study of a sample of 786 patients, 15 years after their first episode of psychosis will be one of the longest and largest conducted to date. Results of the study will inform clinical practice and policy development.
Developing Better Models Of Outcome For Psychotic Disorders
Funder
National Health and Medical Research Council
Funding Amount
$458,695.00
Summary
Research on psychosis has been focused on developing treatments for hallucinations and delusions. However, ‘outcome’ is multifaceted and must embrace functioning, and quality of life. A/Prof Cotton will develop models will comprehensively capture ‘whole person’ outcomes for people who have experienced psychosis. Understanding how the disease impacts on the individual will enable better service planning, and refinement and development of treatments for patients with psychosis.
Early Psychosis Workforce: Development Of Core Competencies For Mental Health Professionals Working In The Field Of Early Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$128,332.00
Summary
I am a mental health clinician with over 10 years experience working with young people. I intend to develop a set of core competencies (knowledge, attitudes, skills) for mental health professionals working with clients who have recently experienced their first epsiode of psychosis and evaluate how the competency standards are implemented in clinical practice.
Molecular And Cellular Characterisation Of Schizophrenia Associated Dysfunction In MicroRNA Biogenesis
Funder
National Health and Medical Research Council
Funding Amount
$496,205.00
Summary
We have identified substantial changes in the biogenesis of microRNA in schizophrenia. These small non-coding molecules derived from junk DNA, play a significant role in genetic regulation, with each one capable of silencing hundreds of target genes. This has major implications for schizophrenia, which is known to involve substantial changes in gene activity. The project will identify the molecular basis of this alteration in gene silencing, and its biological implications for schizophrenia.
Longitudinal Treatment Outcomes For Methamphetamine Dependence: A Treatment Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$720,500.00
Summary
Australia has a substantial and growing population of problematic stimulant users, namely dependent or injecting methamphetamine users, with methamphetamine injection accounting for one-third of all injecting drug use. Methamphetamine dependence has been associated with serious physical and mental health problems, including psychosis, depression, stroke and general poor health and wellbeing. Increasing numbers of people are presenting for treatment of methamphetamine dependence and many are expe ....Australia has a substantial and growing population of problematic stimulant users, namely dependent or injecting methamphetamine users, with methamphetamine injection accounting for one-third of all injecting drug use. Methamphetamine dependence has been associated with serious physical and mental health problems, including psychosis, depression, stroke and general poor health and wellbeing. Increasing numbers of people are presenting for treatment of methamphetamine dependence and many are experiencing other psychiatric problems like drug-induced psychosis and depression. Currently little is known about people who present for treatment of methamphetamine dependence, including how many have other serious mental health problems that need treatment in their own right. Nor is it known whether the treatment they receive for their methamphetamine use is effective in reducing their drug use or improving their mental health status. The current study will provide much needed information on people seeking treatment for methamphetamine dependence in Australia, including their psychiatric status, and whether the treatment they receive for methamphetamine dependence is effective in reducing their drug use and related health problems or improving their mental health status. These aims will be met by assessing drug use, psychiatric status, treatment experience as well as general health and well being among a cohort of people entering treatment for methamphetamine use in Sydney. Responses to treatment will be assessed at 3 months and 12 months following treatment entry and outcomes will be compared to a group of methamphetamine users not receiving treatment. This is the first study in Australia to assess the effectiveness of treatment that is provided to methamphetamine users in an everyday treatment setting. It is also the first study internationally to focus on treatment outcome for methamphetamine dependence in a community setting.Read moreRead less